Opternative Partners With FrameGenie to Offer Online Vision Tests


CHICAGO—Opternative Inc. has partnered with online retailer FrameGenie to provide access to online prescription renewal technology on the FrameGenie eyewear site, according to an announcement on Thursday. Opternative said its full API integration with FrameGenie “will further the guarantee that patients have access to the most affordable, accurate and convenient glasses renewal options available online.” Opternative was the first company to develop an online refractive eye test. FrameGenie, which lists Palm Springs, Fla., as its operations base, offers eyewear for men, women and children with prices “starting at $6.95,” according to its website.

“We are very happy to add FrameGenie to our roster of integrated partners and we look forward to working with their talented team to support the online needs of their patients,” Opternative co-founder Dr. Steven Lee, OD, said in the announcement. The company also works with 1-800 Contacts. Opternative is currently involved in a dispute with Warby Parker over trade secrets about the Opternative technology which led to the filing of lawsuit in late 2017, as VMAIL reported

Opternative named a new chief executive officer, Brent Rasmussen, earlier this month to succeed co-founder Aaron Dallek, as VMAIL reported.  

FrameGenie chief executive officer Daniel Stanton, also leads Vision Precision Holdings as chief executive officer (Vision Precision Holdings is the parent company of My Eyelab and Stanton Optical, according to a spokesperson.

Stanton said, “FrameGenie is excited to offer online vision prescriptions to its customers.” He added, “Used in rotation with comprehensive eye exams, online refractions will provide our patients with the ability to update or renew their glasses prescription from the comfort of their home or even office."

Opternative was founded in 2012, and it launched the first online refractive eye test to deliver a physician-issued prescription for glasses or contact lenses, according to the company.